特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒドロキシクロロキンおよびクロロキンの世界市場:競合・予測・機会 - 種類(注射剤・錠剤)、投与経路(経口・経静脈)、含有量(100mg・250㎎・500㎎)、用途、地域別

Global Hydroxychloroquine and Chloroquine Market, By Type (Injectables & Tablets), Route of Administration (Oral v/s Intravenous), Strength (100mg, 250mg & 500mg), Application, Region, Competition, Forecast & Opportunities, 2030

発行 TechSci Research 商品コード 932038
出版日 ページ情報 英文 114 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

ヒドロキシクロロキンおよびクロロキンの世界市場:競合・予測・機会 - 種類(注射剤・錠剤)、投与経路(経口・経静脈)、含有量(100mg・250㎎・500㎎)、用途、地域別 Global Hydroxychloroquine and Chloroquine Market, By Type (Injectables & Tablets), Route of Administration (Oral v/s Intravenous), Strength (100mg, 250mg & 500mg), Application, Region, Competition, Forecast & Opportunities, 2030
出版日: 2020年04月01日 ページ情報: 英文 114 Pages
概要

世界のヒドロキシクロロキンおよびクロロキン市場は、予測期間中に堅調なペースで成長し、2020年までに市場規模が2倍に拡大する見通しです。ヒドロキシクロロキンはプラケニル、クロロキンはアラレンの商品名で市場で入手可能です。当市場は、新型コロナウイルス感染症(COVID-19)の有病率の上昇によって成長が促進されています。市場規模は2019年に約1億4,000万米ドルと評価され、2020年には2億8,500万米ドルに達すると予測されています。また、アメリカ食品医薬品局(FDA)はヒドロキシクロロキンとクロロキンについて新型コロナウイルス感染症(COVID-19)の治療薬として緊急使用許可を発行しました。

当レポートでは、世界のヒドロキシクロロキンおよびクロロキン市場を調査し、市場の概要、種類・投与経路・含有量・用途・地域別の市場規模の推移と予測、市場の成長要因および課題、市場機会、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

  • ブランド認知度
  • 投与経路
  • 顧客満足度の分析
  • アンメットニーズ/課題

第5章 世界のヒドロキシクロロキンおよびクロロキン市場の概要

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • 種類別
      • 注射剤
      • 錠剤
    • 投与経路別
      • 経口投与
      • 経静脈投与
    • 含有量別
      • 100mg
      • 250mg
      • 500mg
    • 用途別
      • 関節リウマチ
      • マラリア
      • 新型コロナウイルス感染症(COVID-19)
      • その他
    • 企業別
    • 地域別
  • 投与経路市場マップ

第6章 アジア太平洋地域のヒドロキシクロロキンおよびクロロキン市場の展望

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • 種類別
    • 用途別
    • 投与経路別
    • 含有量別
    • 国別
  • 市場分析:国別
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国
    • シンガポール

第7章 欧州のヒドロキシクロロキンおよびクロロキン市場の展望

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • 種類別
    • 用途別
    • 投与経路別
    • 含有量別
    • 国別
  • 市場分析:国別
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 北米のヒドロキシクロロキンおよびクロロキン市場の展望

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • 種類別
    • 用途別
    • 投与経路別
    • 含有量別
    • 国別
  • 市場分析:国別
    • 米国
    • メキシコ
    • カナダ

第9章 南米のヒドロキシクロロキンおよびクロロキン市場の展望

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • 種類別
    • 用途別
    • 投与経路別
    • 含有量別
    • 国別
  • 市場分析:国別
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのヒドロキシクロロキンおよびクロロキン市場の展望

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • 種類別
    • 用途別
    • 投与経路別
    • 含有量別
    • 国別
  • 市場分析:国別
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 市場力学

  • 成長要因
  • 課題

第12章 市場動向

第13章 価格分析

第14章 競合情勢

  • Ipca Laboratories Ltd
  • Zydus Cadila
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
  • Rising Pharma Holdings Inc
  • Abcam plc
  • Mylan N.V
  • Abbott Laboratories
  • Artecef B.V.
  • Uniprix Inc.
  • Recipharm

第15章 戦略的推奨事項

図表

List of Figures

  • Figure 1: Global Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 2: Global Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 3: Global Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 4: Global Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 5: Global Hydroxychloroquine and Chloroquine Share, By Region (USD Million), 2015-2030F
  • Figure 6: Global Hydroxychloroquine and Chloroquine Share, By Company (USD Million), 2015-2030F
  • Figure 7: Global Hydroxychloroquine and Chloroquine Attractiveness Index, By Region, By Value, 2015-2030F
  • Figure 8: Global Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration Type, By Value, 2015-2030F
  • Figure 9: North America Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 10: North America Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 11: North America Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 12: North America Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 13: North America Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 14: North America Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 15: North America Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 16: United States Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 17: United States Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 18: United States Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 19: United States Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 20: United States Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 21: Canada Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 22: Canada Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 23: Canada Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 24: Canada Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 25: Canada Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 26: Mexico Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 27: Mexico Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 28: Mexico Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 29: Mexico Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 30: Mexico Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 31: Europe Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 32: Europe Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 33: Europe Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 34: Europe Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 35: Europe Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 36: Europe Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 37: Europe Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 38: Russia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 39: Russia Kingdom Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 40: Russia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 41: Russia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 42: Russia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 43: United Kingdom Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 44: United Kingdom Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 45: United Kingdom Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 46: United Kingdom Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 47: United Kingdom Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 48: Italy Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 49: Italy Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 50: Italy Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 51: Italy Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 52: Italy Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 53: Germany Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 54: Germany Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 55: Germany Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 56: Germany Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 57: Germany Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 58: Spain Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 59: Spain Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 60: Spain Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 61: Spain Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 62: Spain Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 63: France Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 64: France Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 65: France Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 66: France Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 67: France Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 68: Asia - Pacific Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 69: Asia - Pacific Hydroxychloroquine and Chloroquine Size, By Type(USD Million), 2015-2030F
  • Figure 70: Asia - Pacific Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 71: Asia - Pacific Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 72: Asia - Pacific Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 73: Asia - Pacific Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 74: Asia - Pacific Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 75: China Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 76: China Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 77: China Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 78: China Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 79: China Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 80: China Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 81: India Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 82: India Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 83: India Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 84: India Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 85: India Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 86: Australia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 87: Australia Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 88: Australia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 89: Australia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 90: Australia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 91: Japan Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 92: Japan Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 93: Japan Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 94: Japan Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 95: Japan Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 96: Japan Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 97: Singapore Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 98: Singapore Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 99: Singapore Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 100: Singapore Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 101: Singapore Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 102: South Korea Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 103: South Korea Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 104: South Korea Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 105: South Korea Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 106: South Korea Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 107: South Korea Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 108: Middle East and Africa Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 109: Middle East and Africa Hydroxychloroquine and Chloroquine Size, By Type(USD Million), 2015-2030F
  • Figure 110: Middle East and Africa Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 111: Middle East and Africa Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 112: Middle East and Africa Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 113: Middle East and Africa Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 114: Middle East and Africa Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 115: Saudi Arabia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 116: Saudi Arabia Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 117: Saudi Arabia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 118: Saudi Arabia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 119: Saudi Arabia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 120: UAE Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 121: UAE Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 122: UAE Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 123: UAE Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 124: UAE Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 125: UAE Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 126: South Africa Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 127: South Africa Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 128: South Africa Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 129: South Africa Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 130: South Africa Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 131: South Africa Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 132: Kuwait Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 133: Kuwait Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 134: Kuwait Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 135: Kuwait Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 136: Kuwait Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 137: Kuwait Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 138: South America Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 139: South America Hydroxychloroquine and Chloroquine Size, By Type (USD Million), 2015-2030F
  • Figure 140: South America Hydroxychloroquine and Chloroquine Share, By Route of Administration (USD Million), 2015-2030F
  • Figure 141: South America Hydroxychloroquine and Chloroquine Share, By Application (USD Million), 2015-2030F
  • Figure 142: South America Hydroxychloroquine and Chloroquine Share, By Country (USD Million), 2015-2030F
  • Figure 143: South America Hydroxychloroquine and Chloroquine Attractiveness Index, By Country, By Value, 2015-2030F
  • Figure 144: South America Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 145: Brazil Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 146: Brazil Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 147: Brazil Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 148: Brazil Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 149: Brazil Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 150: Brazil Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 151: Argentina Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 152: Argentina Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 153: Argentina Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 154: Argentina Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 155: Argentina Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
  • Figure 156: Colombia Hydroxychloroquine and Chloroquine Size, By Value (USD Million), 2015-2030F
  • Figure 157: Colombia Hydroxychloroquine and Chloroquine Size, By Type, 2015-2030F
  • Figure 158: Colombia Hydroxychloroquine and Chloroquine Share, By Route of Administration, 2015-2030F
  • Figure 159: Colombia Hydroxychloroquine and Chloroquine Share, By Application, 2015-2030F
  • Figure 160: Colombia Hydroxychloroquine and Chloroquine Share, By Strength, 2015-2030F
  • Figure 161: Colombia Hydroxychloroquine and Chloroquine Attractiveness Index, By Route of Administration, By Value, 2015-2030F
目次
Product Code: 4609

Global hydroxychloroquine and chloroquine market is expected to grow at a robust pace during the forecast period, with the market size expected to double in 2020. Hydroxychloroquine and chloroquine are commonly available in the market under the brand name Aralen and Plaquenil, respectively. Several other formulations of hydroxychloroquine and chloroquine are also available that are sold under different brand names. Chemically, chloroquine is 7-chloro-4-[[4-(diethylamino)-1-methylbutyl] amino] quinoline phosphate (1:2) and is used for the treatment of various diseases such as rheumatoid arthritis, malaria and others.

The global hydroxychloroquine and chloroquine market are driven by the increase in prevalence of COVID-19. In 2019, the market stood at approximately $ 140 million and is expected to reach $ 285 million in 2020. In the recent light of events, FDA issued an Emergency Use Authorization for the treatment of novel coronavirus disease (COVID-19).

Hydroxychloroquine and Chloroquine phosphate belong to the class of antimalarial, amebicides drugs. One of the major applications of Hydroxychloroquine and Chloroquine is for the prevention and treatment of malaria. Globally, Ipca and Cadila are among the top manufacturers of these drugs. The US FDA has recently lifted import alerts on its plants, paving the way for the firms to export the drugs to the US. India is among the major manufacturers of the world's total hydroxychloroquine production and exported worth USD51 million of Hydrochloroquine and Chloroquine and in 2019. China, being the largest manufacturer of APIs, is not producing Hydroxychloroquine because of less cases of malaria.

The global hydroxychloroquine and chloroquine market is segmented based on type, route of administration, strength, application, and region. Based on application, the market can be categorized into rheumatoid arthritis, malaria, COVID-19 and others. In the application segments, COVID-19 is expected to dominate the market due to rising prevalence of this disease.

Furthermore, based on type, the tablet segment is expected to dominate the market due to its cost effectiveness. Among all regions, North America is expected to witness significant growth during the forecast period in the overall hydroxychloroquine and chloroquine market owing to comparatively higher prevalence of COVID-19 .

Major players operating in the global chloroquine market include Ipca Laboratories Ltd, Zydus Cadila, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Rising Pharma Holdings Inc, Abcam plc, Mylan N.V, Abbott and others

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2030

Objective of the Study

  • To analyze and forecast the market size of global hydroxychloroquine and chloroquine market.
  • To classify and forecast global hydroxychloroquine and chloroquine market based on type, route of administration, strength, application, company and regional distribution.
  • To identify drivers and challenges for global hydroxychloroquine and chloroquine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global hydroxychloroquine and chloroquine market.
  • To conduct pricing analysis for global hydroxychloroquine and chloroquine market.
  • To identify and analyze the profile of leading players operating in global hydroxychloroquine and chloroquine market.
  • To examine policy & regulatory landscape for global hydroxychloroquine and chloroquine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of hydroxychloroquine and chloroquine manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players operating across the globe.

TechSci Research calculated the market size of global hydroxychloroquine and chloroquine market using a bottom-up approach, wherein data for various segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Hydroxychloroquine and chloroquine manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to chloroquine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global hydroxychloroquine and chloroquine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Type:

Injectables

Tablets

  • Market, By Route of Administration:

Oral

Intravenous

  • Market, By Strength:

100mg

200mg

250mg

500mg

  • Market, By Application:

Rheumatoid Arthritis

Malaria

COVID-19

Others

  • Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global hydroxychloroquine and chloroquine market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Route of Administration Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

  • 4.1. Brand Awareness (Aided/Unaided)
  • 4.2. Route of Administration Awareness
  • 4.3. Customer Satisfaction Analysis
  • 4.4. Unmet Needs/Challenges

5. Global Hydroxychloroquine & Chloroquine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Injectables, Tablets)
    • 5.2.2. By Route of Administration (Oral v/s Intravenous)
    • 5.2.3. By Strength (100mg,200mg, 250mg, 500mg,)
    • 5.2.4. By Application (Rheumatoid Arthritis, Malaria, COVID-19, Others)
    • 5.2.5. By Company (2019)
    • 5.2.6. By Region
  • 5.3. Route of Administration Market Map

6. Asia-Pacific Hydroxychloroquine & Chloroquine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Route of Administration
    • 6.2.4. By Strength
    • 6.2.5. By Country
  • 6.3. Asia-Pacific: Country Analysis
    • 6.3.1. China Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Strength
    • 6.3.2. India Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Strength
    • 6.3.3. Australia Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Strength
    • 6.3.4. Japan Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By Route of Administration
        • 6.3.4.2.4. By Strength
    • 6.3.5. South Korea Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Application
    • 6.3.6. Singapore Hydroxychloroquine & Chloroquine Market Outlook
      • 6.3.6.1. Market Size & Forecast
        • 6.3.6.1.1. By Value
      • 6.3.6.2. Market Share & Forecast
        • 6.3.6.2.1. By Type
        • 6.3.6.2.2. By Application
        • 6.3.6.2.3. By Route of Administration
        • 6.3.6.2.4. By Strength

7. Europe Hydroxychloroquine & Chloroquine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Route of Administration
    • 7.2.4. By Strength
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Strength
    • 7.3.2. Germany Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Strength
    • 7.3.3. United Kingdom Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Strength
    • 7.3.4. Italy Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Strength
    • 7.3.5. Spain Hydroxychloroquine & Chloroquine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Strength

8. North America Hydroxychloroquine & Chloroquine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Route of Administration
    • 8.2.4. By Strength
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Hydroxychloroquine & Chloroquine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Strength
    • 8.3.2. Mexico Hydroxychloroquine & Chloroquine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Strength
    • 8.3.3. Canada Hydroxychloroquine & Chloroquine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Strength

9. South America Hydroxychloroquine & Chloroquine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Route of Administration
    • 9.2.4. By Strength
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hydroxychloroquine & Chloroquine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Strength
    • 9.3.2. Argentina Hydroxychloroquine & Chloroquine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Strength
    • 9.3.3. Colombia Hydroxychloroquine & Chloroquine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Strength

10. Middle East and Africa Hydroxychloroquine & Chloroquine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Route of Administration
    • 10.2.4. By Strength
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Strength
    • 10.3.2. Saudi Arabia Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Strength
    • 10.3.3. UAE Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Strength
    • 10.3.4. Kuwait Hydroxychloroquine & Chloroquine Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By Route of Administration
        • 10.3.4.2.4. By Strength

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Pricing Analysis

14. Competitive Landscape

  • 14.1. Ipca Laboratories Ltd
  • 14.2. Zydus Cadila
  • 14.3. Novartis AG
  • 14.4. Teva Pharmaceutical Industries Ltd
  • 14.5. Bayer AG
  • 14.6. Rising Pharma Holdings Inc
  • 14.7. Abcam plc
  • 14.8. Mylan N.V
  • 14.9. Abbott Laboratories
  • 14.10. Artecef B.V.
  • 14.11. Uniprix Inc.
  • 14.12. Recipharm

15. Strategic Recommendations